Dr. Skoulidis on Combining Chemotherapy and Immunotherapy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP
Published Online: Friday, Nov 10, 2017



Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non–small cell lung cancer (NSCLC).

The KEYNOTE-021 data suggested a combination of pembrolizumab (Keytruda) with carboplatin/pemetrexed was associated with a 55% objective response rate, almost more than a chemotherapy doublet alone.

Combining chemotherapy with immunotherapy benefited PD-L1–negative tumors and has an additive effect, so it would be a valid treatment option for patients who express low levels of PD-L1, explains Skoulidis.


Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non–small cell lung cancer (NSCLC).

The KEYNOTE-021 data suggested a combination of pembrolizumab (Keytruda) with carboplatin/pemetrexed was associated with a 55% objective response rate, almost more than a chemotherapy doublet alone.

Combining chemotherapy with immunotherapy benefited PD-L1–negative tumors and has an additive effect, so it would be a valid treatment option for patients who express low levels of PD-L1, explains Skoulidis.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x